| dc.creator |
Sanmartí Sala, Raimon |
|
| dc.creator |
Graell, Eduard |
|
| dc.creator |
Pérez, María L. |
|
| dc.creator |
Ercilla González, M. Guadalupe |
|
| dc.creator |
Viñas, Odette |
|
| dc.creator |
Gómez-Puerta, José Alfredo |
|
| dc.creator |
Gratacós Masmitjà, Jordi |
|
| dc.creator |
Balsa, Alejandro |
|
| dc.creator |
Gómara Elena, María José |
|
| dc.creator |
Larrosa, Marta |
|
| dc.creator |
Cañete Crespillo, Juan D. |
|
| dc.creator |
Haro Villar, Isabel |
|
| dc.date |
2010-11-19T11:30:09Z |
|
| dc.date |
2010-11-19T11:30:09Z |
|
| dc.date |
2009-09-02 |
|
| dc.date.accessioned |
2024-12-16T10:25:33Z |
|
| dc.date.available |
2024-12-16T10:25:33Z |
|
| dc.identifier |
1478-6362 |
|
| dc.identifier |
http://hdl.handle.net/2445/14462 |
|
| dc.identifier |
19725967 |
|
| dc.identifier.uri |
http://fima-docencia.ub.edu:8080/xmlui/handle/123456789/19619 |
|
| dc.description |
Introduction: Evidence suggests that citrullinated fibrin(ogen) may be a potential in vivo target of anticitrullinated protein/peptide antibodies (ACPA) in rheumatoid arthritis (RA). We compared the diagnostic yield of three enzyme-linked immunosorbent assay (ELISA) tests by using chimeric fibrin/filaggrin citrullinated synthetic peptides (CFFCP1, CFFCP2, CFFCP3) with a commercial CCP2-based test in RA and analyzed their prognostic values in early RA. Methods: Samples from 307 blood donors and patients with RA (322), psoriatic arthritis (133), systemic lupus erythematosus (119), and hepatitis C infection (84) were assayed by using CFFCP- and CCP2-based tests. Autoantibodies also were analyzed at baseline and during a 2-year follow-up in 98 early RA patients to determine their prognostic value. Results: With cutoffs giving 98% specificity for RA versus blood donors, the sensitivity was 72.1% for CFFCP1, 78.0% for CFFCP2, 71.4% for CFFCP3, and 73.9% for CCP2, with positive predictive values greater than 97% in all cases. CFFCP sensitivity in RA increased to 80.4% without losing specificity when positivity was considered as any positive anti-CFFCP status. Specificity of the three CFFCP tests versus other rheumatic populations was high (> 90%) and similar to those for the CCP2. In early RA, CFFCP1 best identified patients with a poor radiographic outcome. Radiographic progression was faster in the small subgroup of CCP2-negative and CFFCP1-positive patients than in those negative for both autoantibodies. CFFCP antibodies decreased after 1 year, but without any correlation with changes in disease activity. Conclusions: CFFCP-based assays are highly sensitive and specific for RA. Early RA patients with anti-CFFCP1 antibodies, including CCP2-negative patients, show greater radiographic progression. |
|
| dc.format |
9 p. |
|
| dc.format |
application/pdf |
|
| dc.language |
eng |
|
| dc.publisher |
BioMed Central |
|
| dc.relation |
Reproducció del document publicat a http://dx.doi.org/10.1186/ar2802 |
|
| dc.relation |
Arthritis Research and Therapy, 2009, 11:R135 |
|
| dc.relation |
http://dx.doi.org/10.1186/ar2802 |
|
| dc.rights |
cc-by, (c) Sanmarti et al., 2009 |
|
| dc.rights |
http://creativecommons.org/licenses/by/2.0/ |
|
| dc.rights |
info:eu-repo/semantics/openAccess |
|
| dc.source |
Articles publicats en revistes (Medicina) |
|
| dc.subject |
Artritis reumatoide |
|
| dc.subject |
Diagnòstic |
|
| dc.subject |
Rheumatoid arthritis |
|
| dc.subject |
Diagnosis |
|
| dc.title |
Diagnostic and prognostic value of antibodies against chimeric fibrin/filaggrin citrullinated synthetic peptides in rheumatoid arthritis |
|
| dc.type |
info:eu-repo/semantics/article |
|
| dc.type |
info:eu-repo/semantics/publishedVersion |
|